Welcome!
Biolidics Limited
Medtech
Biolidics reallocates $670,000 of rights issue proceeds to Biomedics Lab acquisition
The proceeds from the rights issue was originally intended to be used for the company’s working capital purposes.
November 23, 2023
Company in the news
UOB will no longer sponsor Biolidics after Dec 31
The Covid-19 test kit provider is currently “actively seeking” to appoint a new sponsor.
September 28, 2023
Covid-19
Biolidics receives authorisation from Indonesian health ministry for Covid-19 test kits
Biolidics' ClearEpi antigen rapid test kit has been authorised for usage in Indonesia.
March 16, 2021
SGX query
Biolidics triggers SGX query on share price surge before licensing agreement announcement
Between July 9 and 14, Biolidics’ share price surged 67.7% to 52 cents on the 14th, from 31 cents when markets opened on the 9th.
July 15, 2020
Deals, joint ventures & alliances
Biolidics collaborates with Hangzhou Normal University to undertake clinical investigations for lung cancer biomarker
SINGAPORE (Sept 9): Biolidics, the medical technology company, is collaborating with Hangzhou Normal University to undertake clinical investigations to validate the clinical utility of CTCs as a biomarker in late stage lung cancer.
September 09, 2019
Deals, joint ventures & alliances
Biolidics partners Japan's Sysmex Corp for cancer-related R&D
SINGAPORE (Feb 20): Biolidics Limited has established a strategic partnership with Sysmex Corporation, a Tokyo Stock Exchange-listed supplier of hematology instruments, to collaborate on the development of laboratory assays in the field of circulating tum
February 20, 2019